{
    "clinical_study": {
        "@rank": "38435", 
        "arm_group": [
            {
                "arm_group_label": "Oral protein supplement (Tested product)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Iso-caloric supplement (Control product)", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This multicentre, randomised, double-blind, 2-parallel group, controlled trial aims to\n      investigate whether oral milk protein supplements led to increase in serum Insulin-like\n      Growth Factor-I levels (IGF-I) as compared with a control group fed with an iso-caloric\n      supplement, in women with anorexia nervosa. Subjects receive either 150g/day of tested\n      product or control product for 4-week, followed by a 4-week follow-up."
        }, 
        "brief_title": "Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa", 
        "completion_date": {
            "#text": "April 2009", 
            "@type": "Actual"
        }, 
        "condition": "Anorexia Nervosa", 
        "condition_browse": {
            "mesh_term": [
                "Anorexia", 
                "Anorexia Nervosa"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study centres: 4 active centres in France and 2 active centres in Switzerland"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged between 18 to 40 years (bounds included).\n\n          -  Women with a serum IGF-I level below the 25th percentile of the reference value\n             according to the age (bounds included).\n\n          -  Women who had given written inform consent.\n\n          -  Women with DSM-IV-confirmed anorexia nervosa lasting for at least 6 months. Women\n             with concomitant binge eating and purging type are also included.\n\n          -  Women admitted in-hospital for weight and nutritional rehabilitation. It is\n             anticipated that the patient will stay in-hospital during the full duration of the\n             4-week supplementation phase, and at least 5 weeks within the study.\n\n          -  Women being already regular consumers of dairy products.\n\n          -  For women with childbearing potential, use of a contraceptive method.\n\n          -  Discontinuation of any mineral and vitamin supplements containing calcium and vitamin\n             D, 1 week before starting the product consumption and during the study.\n\n        Exclusion Criteria:\n\n          -  Women with primary amenorrhea;\n\n          -  Women with lactose intolerance;\n\n          -  Women with any other metabolic disease that could affect bone metabolism:\n             osteogenesis imperfecta, Paget's disease of bone, hyperthyroidism, primary\n             hyperparathyroidism;\n\n          -  Women with current or past neoplasm;\n\n          -  Women with any other severe comorbidity;\n\n          -  Pregnant or breast feeding women;\n\n          -  Women with epilepsy;\n\n          -  Women with any current or past use of the following treatments: bisphosphonates,\n             calcitonin, steroids;\n\n          -  Patients enrolled in another clinical study within the last 4 weeks;\n\n          -  Patients having already received oral nutritional supplements or who need to receive\n             other oral or intravenous (IV) supplements during the follow-up;\n\n          -  Patients having received oral or IV nutritional supplements within two weeks before\n             the inclusion;\n\n          -  Patients having willed to participate in another clinical study during the present\n             study phase and 4 weeks after the end of their participation in the present study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823822", 
            "org_study_id": "07-182", 
            "secondary_id": "NU185"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oral protein supplement (Tested product)", 
                "description": "Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.", 
                "intervention_name": "Oral protein supplement (Tested product)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Iso-caloric supplement (Control product)", 
                "description": "Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.", 
                "intervention_name": "Iso-caloric supplement (Control product)", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Mitogens"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anorexia nervosa", 
            "Protein supplements", 
            "IGF-I"
        ], 
        "lastchanged_date": "April 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Geneva", 
                    "country": "Switzerland"
                }, 
                "name": "Bone Diseases Service, Geneva University Hospitals"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa", 
        "overall_official": {
            "affiliation": "Bone Diseases Service, Department of Internal Medicine Specialties, University Hospitals and Faculty of Medicine of Geneva", 
            "last_name": "Ren\u00e9 Rizzoli, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The main study product effect criterion is the IGF-I level over the 4-week consumption period.", 
            "measure": "Serum insulin like growth factor-1 (IGF-I) level", 
            "safety_issue": "No", 
            "time_frame": "4-week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823822"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Geneva", 
            "investigator_full_name": "Rene Rizzoli", 
            "investigator_title": "Ren\u00e9 Rizzoli, MD (Principal Investigator)", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University Hospital, Geneva", 
        "sponsors": {
            "collaborator": {
                "agency": "Danone Research", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Geneva", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}